Skip to main content
Top

Cancer Immunology, Immunotherapy

Issue 6/2012

Content (19 Articles)

Review

Tumor microenvironment and lymphocyte infiltration

Gwendoline Rahir, Muriel Moser

Open Access Opinion Paper

Reflections upon human cancer immune responsiveness to T cell-based therapy

Ena Wang, Sara Tomei, Francesco M. Marincola

Original article

Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen

Neil L. Berinstein, Gregory T. Wolf, Paul H. Naylor, Lorraine Baltzer, James E. Egan, Harvey J. Brandwein, Theresa L. Whiteside, Lynn C. Goldstein, Adel El-Naggar, Cecile Badoual, Wolf-Herve Fridman, J. Michael White, John W. Hadden

Original article

A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma

Theresa L. Whiteside, Lisa H. Butterfield, Paul H. Naylor, James E. Egan, John W. Hadden, Lorraine Baltzer, Gregory T. Wolf, Neil L. Berinstein

Original article

Expression of antigen processing and presenting molecules in brain metastasis of breast cancer

Yan Liu, Yoshihiro Komohara, Natalie Domenick, Masasuke Ohno, Maki Ikeura, Ronald L. Hamilton, Craig Horbinski, Xinhui Wang, Soldano Ferrone, Hideho Okada

Original Article

Genome-wide differential genetic profiling characterizes colorectal cancers with genetic instability and specific routes to HLA class I loss and immune escape

Mónica Bernal, Fernando García-Alcalde, Angel Concha, Carlos Cano, Armando Blanco, Federico Garrido, Francisco Ruiz-Cabello

Original article

Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide dose

Tanja Lövgren, Petra Baumgaertner, Sébastien Wieckowski, Estelle Devêvre, Philippe Guillaume, Immanuel Luescher, Nathalie Rufer, Daniel E. Speiser

Original article

Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines

I. Poschke, Y. Mao, L. Adamson, F. Salazar-Onfray, G. Masucci, R. Kiessling

Original article

Immunotherapy with IL-10- and IFN-γ-producing CD4 effector cells modulate “Natural” and “Inducible” CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer

Mark J. Dobrzanski, Kathleen A. Rewers-Felkins, Khaliquzzaman A. Samad, Imelda S. Quinlin, Catherine A. Phillips, William Robinson, David J. Dobrzanski, Stephen E. Wright

Original Article

Calreticulin as a potential diagnostic biomarker for lung cancer

Rongrong Liu, Jiuyu Gong, Jun Chen, Qi Li, Chaojun Song, Jian Zhang, Yongming Li, Zhijia Liu, Yun Dong, Lihua Chen, Boquan Jin

Original article

Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria

Marzia Palma, Lotta Hansson, Aniruddha Choudhury, Barbro Näsman-Glaser, Ingrid Eriksson, Lars Adamson, Eva Rossmann, Karin Widén, Rudolf Horváth, Parviz Kokhaei, Simona Vertuani, Håkan Mellstedt, Anders Österborg

Original article

Remodeling of the epitope repertoire of a candidate idiotype vaccine by targeting to lysosomal degradation in dendritic cells

Debora Martorelli, Giuseppe Coppotelli, Elena Muraro, Riccardo Dolcetti, Maria G. Masucci

Original Article

CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice

Jon Hansen, Thomas Lindenstrøm, Julie Lindberg-Levin, Claus Aagaard, Peter Andersen, Else Marie Agger

Open Access Original article

The additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progression

Caroline Schroten, Natasja F. Dits, Ewout W. Steyerberg, Ries Kranse, Arno G. J. L. H. van Leenders, Chris H. Bangma, Robert Kraaij

Original article

Regulatory T cells increase in breast cancer and in stage IV breast cancer

Zhi-kuan Wang, Bo Yang, Hui Liu, Yi Hu, Jun-lan Yang, Liang-liang Wu, Zhen-hong Zhou, Shun-chang Jiao

Original article

Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor

Adam T. Waickman, Angela Alme, Liana Senaldi, Paul E. Zarek, Maureen Horton, Jonathan D. Powell

Original Article

Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck

Anna-Maria A. De Costa, Corinne A. Schuyler, David D. Walker, M. Rita I. Young

Open Access Short communication

Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients

Emilie P. Buddingh, S. Eriaty N. Ruslan, Dagmar Berghuis, Hans Gelderblom, Jakob K. Anninga, Pancras C. W. Hogendoorn, R. Maarten Egeler, Marco W. Schilham, Arjan C. Lankester

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine